Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

Abstract Chimeric antigen receptor-engineered T (CAR-T) cells have shown promising efficacy in patients with relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL). However, challenges remain including long manufacturing processes that need to be overcome. We presented the CD19-targetin...

Full description

Bibliographic Details
Main Authors:	Cheng Zhang, Jiaping He, Li Liu, Jishi Wang, Sanbin Wang, Ligen Liu, Jian Ge, Lei Gao, Li Gao, Peiyan Kong, Yao Liu, Jia Liu, Yu Han, Yongliang Zhang, Zhe Sun, Xun Ye, Wenjie Yin, Martina Sersch, Lianjun Shen, Wei William Cao, Xi Zhang
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-06-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-022-00688-4

Similar Items

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
by: Junfang Yang, et al.
Published: (2022-07-01)

P369: DONOR-DERIVED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE 1 TRIAL
by: Yi Luo, et al.
Published: (2023-08-01)

Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia
by: Xiangqun Li, et al.
Published: (2022-05-01)

Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma
by: Zili Lin, et al.
Published: (2021-09-01)

The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
by: Dristhi Ragoonanan, et al.
Published: (2022-09-01)

S113: IMPACT OF IKZF1 DELETION IN RELAPSED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CD19-CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
by: Zihong Cai, et al.
Published: (2023-08-01)

Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission
by: Guan-hua Hu, et al.
Published: (2022-01-01)

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
by: Na Yang, et al.
Published: (2024-03-01)

Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
by: Xiangyu Zhao, et al.
Published: (2023-08-01)

Next‐generation sequencing reveals the presence of DDX41 mutations in acute lymphoblastic leukemia and aplastic anemia
by: Yang Zhang, et al.
Published: (2021-08-01)

Galunisertib enhances chimeric antigen receptor-modified T cell function
by: Zhixiong Wang, et al.
Published: (2020-06-01)

Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia
by: Josephine Emole, et al.
Published: (2023-01-01)

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity
by: Yan Sun, et al.
Published: (2023-12-01)

Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia
by: Lijuan Wu, et al.
Published: (2023-05-01)

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
by: Mingxue Fan, et al.
Published: (2017-08-01)

P1283: ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR THERAPY FOLLOWED BY UMBILICAL CORD BLOOD TRANSPLANTATION IN PEDIATRIC RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: GOOD SURVIVAL AND LESS GVHD
by: Fang Liu
Published: (2023-08-01)

Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia
by: Ibrahim Aldoss, et al.
Published: (2023-07-01)

Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor
by: Shumin Chen, et al.
Published: (2023-06-01)

Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer
by: Li Yin, et al.
Published: (2023-06-01)

Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
by: Beibei Zhang, et al.
Published: (2024-01-01)

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
by: Chang Liu, et al.
Published: (2023-08-01)

Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure
by: Shuang Li, et al.
Published: (2023-11-01)

Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain
by: Ang Zhang, et al.
Published: (2023-09-01)

Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
by: Yaru Feng, et al.
Published: (2021-01-01)

Engineering chimeric antigen receptor T cells for solid tumour therapy
by: Longwei Liu, et al.
Published: (2022-12-01)

The Importance of Rare Genes on the Prognosis of B-cell Acute Lymphoblastic Leukemia
by: Li Xiang, et al.
Published: (2024-03-01)

Is there a role for B lymphocyte chimerism in the monitoring of B-acute lymphoblastic leukemia patients receiving allogeneic stem cell transplantation?
by: Yi-Ning Yang, et al.
Published: (2015-03-01)

Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
by: Jianxia Zhou, et al.
Published: (2019-06-01)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
by: Jing Ding, et al.
Published: (2022-09-01)

CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months
by: Zhenzhen Yao, et al.
Published: (2023-05-01)

Leishmania donovani visceral leishmaniasis diagnosed by metagenomics next-generation sequencing in an infant with acute lymphoblastic leukemia: a case report
by: Li Chang, et al.
Published: (2023-06-01)

Editorial: Pediatric acute lymphoblastic leukemia: what's next?
by: J. V. Gil, et al.
Published: (2024-01-01)

Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy
by: Heng Mei, et al.
Published: (2022-07-01)

S240: CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS BRIDGING TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVED DISEASE-FREE SURVIVAL IN REFRACTORY/RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
by: Z. Li, et al.
Published: (2022-06-01)

Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12
by: Xiaowei Chi, et al.
Published: (2019-08-01)

Chimeric antigen receptor engineered natural killer cells for cancer therapy
by: Yalan Zhang, et al.
Published: (2023-08-01)

Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance
by: Qunfang Zhang, et al.
Published: (2018-10-01)

Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis
by: Haiyong Wang, et al.
Published: (2021-01-01)

Current and future perspectives of chimeric antigen receptors against glioblastoma
by: Siller-Farfán, JA, et al.
Published: (2022)

A machine learning-based model for the next 3-day geomagnetic index (Kp) forecast
by: Jingjing Wang, et al.
Published: (2023-02-01)